Cyclin-dependent kinase 9

Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

Retrieved on: 
Thursday, February 25, 2021
Branches of biology, Biology, Transcription factors, Cell Cycle, Myc, Oncogenes, Proteins, Cyclin-dependent kinase 9, Androgen receptor, Cyclin K, Cyclin T1

Scientific research has established that MYC requires CDK9 to drive its own expression and to drive expression of its target genes.

Key Points: 
  • Scientific research has established that MYC requires CDK9 to drive its own expression and to drive expression of its target genes.
  • The open-label, multi-center Phase 1/2 clinical trial of KB-0742 is expected to enroll approximately 100 patients with advanced solid tumors or non-Hodgkin lymphoma.
  • Kronos Bio leverages its SMM screening platform to conduct high-throughput screens against traditionally undruggable target proteins, in particular transcription factors.
  • The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

Retrieved on: 
Monday, December 7, 2020
Branches of biology, Biology, Cell Cycle, Transcription factors, Proteins, Oncogenes, Cyclin-dependent kinase 9, Myc

FDA clearance of the IND for KB-0742 marks an important milestone for this program, which was generated using our proprietary drug discovery platform.

Key Points: 
  • FDA clearance of the IND for KB-0742 marks an important milestone for this program, which was generated using our proprietary drug discovery platform.
  • The open-label, Phase 1/2 clinical trial for KB-0742 will be conducted over two stages: dose escalation and expansion.
  • Kronos Bio expects to report initial safety, PK and PD data from the dose-escalation stage of the study in 2021.
  • The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

Vincera Pharma, Inc Announces Exclusive License Agreement for Oncology Portfolio Including a Clinical-stage PTEFb/CDK9 Inhibitor and a Preclinical Bioconjugation Platform

Retrieved on: 
Thursday, October 8, 2020
Branches of biology, Proteins, Biology, Natural sciences, Biochemistry, Bioconjugation, Chemical bonding, Cyclin-dependent kinase 9, P-TEFb, Antibody-drug conjugate

Under the terms of the license agreement, Vincera will in-license VIP152 (formerly BAY 1251152), a clinical-stage, highly selective, positive transcription elongation factor b (PTEFb)/cyclin-dependent kinase 9 (CDK9) inhibitor for the treatment of cancer.

Key Points: 
  • Under the terms of the license agreement, Vincera will in-license VIP152 (formerly BAY 1251152), a clinical-stage, highly selective, positive transcription elongation factor b (PTEFb)/cyclin-dependent kinase 9 (CDK9) inhibitor for the treatment of cancer.
  • Additionally, Vincera will receive assets and license technology for a preclinical bioconjugation platform to address the limitations of small-molecule and antibody-drug conjugates in oncology.
  • Dr. Hamdy continued, In addition to our planned clinical program, we intend to advance, in parallel, the development of our preclinical bioconjugation platform.
  • In exchange for this license, Vincera will pay Bayer an upfront license fee and development and commercial sales milestone payments.

Tolero Pharmaceuticals Presents Findings from First Clinical Studies Evaluating Investigational Agents TP-1287 and TP-3654 in Patients with Advanced Solid Tumors at ASCO Virtual Annual Meeting 2020

Retrieved on: 
Friday, May 29, 2020
Organic compounds, Branches of biology, Heterocyclic compounds, Cell Cycle, Cyclin-dependent kinase 9, Proteins, Lactams, Protein kinase inhibitors, Indoles, Brivanib alaninate

TP-1287 is an investigational oral cyclin-dependent kinase 9 (CDK9) inhibitor under evaluation in a Phase 1 study in patients with advanced solid tumors ( NCT03604783 ).

Key Points: 
  • TP-1287 is an investigational oral cyclin-dependent kinase 9 (CDK9) inhibitor under evaluation in a Phase 1 study in patients with advanced solid tumors ( NCT03604783 ).
  • The organizations apply their expertise and collaborate to achieve a common objective - expediting the discovery, development and commercialization of novel treatment options.
  • Any forward-looking statements set forth in this press release speak only as of the date of this press release.
  • "A Phase I, First-in-human, Open-label, Dose escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1287 Administered Daily to Patients with Advanced Solid Tumors."